Immix Biopharma, Inc. (IMMX) vs Monopar Therapeutics Inc. (MNPR)
A side-by-side comparison of Immix Biopharma, Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMMX
Immix Biopharma, Inc.
$9.72HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
MNPR
Monopar Therapeutics Inc.
$80.46HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — IMMX vs MNPR
growth of $100 · dividends reinvested · last 5yIMMX +176.0% (+22.5%/yr)MNPR +305.6% (+32.3%/yr)MNPR compounded faster over this window
IMMX MNPR
IMMX vs MNPR: by the numbers
- •MNPR is the larger company ($539M vs $529M market cap).
Metrics side by side
Valuation
| Metric | IMMX | MNPR |
|---|---|---|
| P/B ratio | 2.31 | 4.12 |
Profitability
| Metric | IMMX | MNPR |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -17.44% | -13.64% |
| ROIC | -18.20% | -16.89% |
Growth (annualized)
| Metric | IMMX | MNPR |
|---|---|---|
| Total return CAGR (5Y) | N/A | 27.38% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.